Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMA · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| SGN-CD33A + HMA | EXPERIMENTAL | SGN-CD33A with hypomethylating agent |
| SGN-CD33A Monotherapy | EXPERIMENTAL | SGN-CD33A |
| Name | Type | Description |
|---|---|---|
| HMA | DRUG | azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days |
| SGN-CD33A | DRUG | Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA) |
Inclusion Criteria: * Acute myeloid leukemia, positive for CD33 * Eastern Cooperative Oncology Group status of 0 or 1 * Adequate baseline renal and hepatic function * Central venous access * Either achieved complete remission (greater than 12 weeks in duration) with initial induction/consolidation ...
HMA is an investigational small molecule developed by Pfizer, Inc. for acute myelogenous leukemia (AML), a cancer of the blood and bone marrow. It is in Phase 1 clinical development and has been studied in a completed safety trial. HMA is a biomarker-selected therapy, meaning treatment is directed at patients whose disease expresses a specific marker.
HMA is being developed for the treatment of acute myelogenous leukemia, also called acute myeloid leukemia or AML. The clinical program has also included patients with acute promyelocytic leukemia. It is an investigational agent in Phase 1 development and is not an established treatment option for AML.
HMA is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical program evaluating HMA in acute myelogenous leukemia. The drug is a small molecule in Phase 1 development.
HMA is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 1 program in acute myelogenous leukemia has been completed, and no trials of HMA are currently listed as active.
HMA has been evaluated in one completed Phase 1 trial, NCT01902329, titled A Safety Study of SGN-CD33A in AML Patients. The trial enrolled 195 participants aged 18 years and older in the United States and included patients with acute myelogenous leukemia, acute myeloid leukemia, and acute promyelocytic leukemia. It was a controlled study without randomization or double blinding.
Yes. HMA is a biomarker-selected therapy, meaning its development targets patients whose disease carries a specific biological marker rather than an unselected AML population. This approach is intended to focus treatment on patients most likely to respond. HMA remains an investigational small molecule in Phase 1 development for acute myelogenous leukemia.